AstraZeneca PLC (AZNCF)
Data as of October 19, 2026 · Drug Manufacturers - General
Stockbruh grade: Challenging 0/5 metrics rated Sunny
What does AstraZeneca PLC do?
AstraZeneca PLC functions as a global biopharmaceutical enterprise, committed to the entire process of pharmaceutical innovation, spanning from the initial discovery and development stages to the manufacturing and market introduction of its prescription medications. The company boasts a comprehensive portfolio of drugs addressing a diverse array of therapeutic areas. This encompasses a robust selection for oncology, featuring key treatments such as Calquence, Enhertu, and Tagrisso, alongside vital therapies for cardiovascular, renal, and metabolic conditions, including Farxiga/Forxiga and Brilinta/Brilique. Its offerings further extend to impactful medications for respiratory and immunological ailments like Symbicort and Fasenra, as well as specialized remedies for rare diseases, notably Soliris and Ultomiris.
Key Numbers
| Metric | Rating | What it means |
|---|
| Returns (5Y) | ⛅ Moderate | 5-year price performance |
| Profitability | ⛅ Moderate | Net margin & return on equity |
| Growth | ⛅ Moderate | Revenue & earnings trend |
| Earnings | ⛅ Moderate | EPS vs analyst expectations |
| Cash & Debt | ⛅ Moderate | Balance sheet strength |
| Price | $189.90 | Market Cap | — |
| Exchange | OTC | | |
Plain-English Analysis
What's it worth?
Performance has been moderate. Sign up free to see Stockbruh's full valuation analysis including price ratios and plain-English commentary.
How the business works
AstraZeneca PLC functions as a global biopharmaceutical enterprise, committed to the entire process of pharmaceutical innovation, spanning from the initial discovery and development stages to the manufacturing and market introduction of its prescription medications. The company boasts a comprehensive portfolio of drugs addressing a diverse array of therapeutic areas. Sign up free for competitor and revenue breakdown ↗
Are they building the future?
Growth is mixed — some positive signals, but not consistent. Sign up free for Stockbruh's full growth breakdown.
What's ahead?
Earnings are mixed. Sign up free for the full earnings picture including EPS history and analyst forecasts.